About Conference

We are delighted to invite you to the “3rd International Conference on COPD and Asthma” in the historic city of Rome, Italy, on May 12-13, 2025. This prestigious event will bring together researchers, academics, industry professionals, and enthusiasts under the theme "Addressing Challenges in COPD and Asthma Prevention and Management." The conference will serve as a pivotal platform for exploring novel treatments, innovative therapies, and comprehensive strategies in respiratory healthcare.

COPD SUMMIT 2025 will cover a wide range of topics crucial to understanding and combating respiratory diseases, from pathophysiology and pharmacology to critical care and emerging challenges like lung health amidst COVID-19. Participants can engage in presentations, workshops, and panel discussions on the latest research findings, advancements in diagnostic tools, and preventive measures. Join us in Rome or virtually as we enhance our understanding of respiratory health and work towards impactful interventions. We look forward to welcoming you to this significant event in pulmonary healthcare.

Sessions and Tracks

Track 01: Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition characterized by persistent respiratory symptoms and airflow limitation, primarily caused by long-term exposure to harmful particles or gases, most commonly from smoking. It includes chronic bronchitis and emphysema, leading to significant breathing difficulties, reduced quality of life, and increased risk of respiratory infections. Effective management involves medication, lifestyle changes, and pulmonary rehabilitation to slow disease progression and improve patient outcomes.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 02: Asthma Management

Asthma management involves controlling symptoms and preventing attacks through a combination of medication and lifestyle adjustments. Inhaled corticosteroids and bronchodilators are commonly used to reduce inflammation and open airways, while avoiding triggers such as allergens and irritants is crucial. Regular monitoring and a personalized action plan help patients maintain optimal control and minimize the impact of asthma on daily life.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 03: Asthma-COPD Overlap

Asthma-COPD overlap (ACO) is a condition where individuals exhibit features of both asthma and chronic obstructive pulmonary disease (COPD). It presents challenges in diagnosis and management, as patients experience persistent airflow limitation and respiratory symptoms typical of both diseases. Effective treatment requires a tailored approach that addresses the unique characteristics of ACO, often involving a combination of asthma and COPD therapies to optimize symptom control and improve quality of life.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track04: COPD Pathogenesis

COPD pathogenesis involves chronic inflammation and structural changes in the lungs due to prolonged exposure to irritants, primarily tobacco smoke. This inflammation leads to the progressive destruction of lung tissue, including the loss of alveolar structures and airway remodeling. These changes result in persistent airflow limitation, decreased lung function, and symptoms such as chronic cough and breathlessness, ultimately impairing respiratory health.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 05: Pathophysiology & Pharmacology

Pathophysiology and pharmacology are critical in understanding and treating respiratory diseases. Pathophysiology explores the underlying mechanisms of disease development and progression, such as inflammation and airway remodeling in conditions like asthma and COPD. Pharmacology focuses on how medications interact with these pathophysiological processes to alleviate symptoms and modify disease progression, guiding the development of effective treatments and optimizing therapeutic strategies.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 06: Drug Discovery of COPD

Drug discovery for COPD aims to identify new medications that target the underlying mechanisms of the disease, such as inflammation and airflow obstruction. This process involves screening for compounds that can improve lung function, reduce symptoms, and slow disease progression. Advances in drug discovery are essential for developing more effective therapies that can enhance the quality of life for individuals with COPD.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 07: COPD Preventative Measures

Preventative measures for COPD include avoiding exposure to tobacco smoke and environmental pollutants, maintaining a healthy lifestyle, and managing risk factors such as respiratory infections and occupational hazards. Early intervention through regular screenings and vaccinations can also help reduce the risk of disease onset and progression, ultimately promoting better lung health and preventing severe complications.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 08: Pharmacological and Non-Pharmacological Treatments

Pharmacological and non-pharmacological treatments for respiratory diseases encompass a range of strategies to manage symptoms and improve quality of life. Pharmacological treatments include medications like inhaled corticosteroids and bronchodilators, which target inflammation and airway constriction. Non-pharmacological approaches involve lifestyle modifications such as smoking cessation, physical exercise, and pulmonary rehabilitation, which complement drug therapy by enhancing overall lung function and patient well-being.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 09: Spirometry

Spirometry is a key diagnostic tool used to assess lung function by measuring airflow and volume during breathing. It helps in diagnosing and monitoring respiratory conditions like asthma and COPD by evaluating parameters such as forced expiratory volume (FEV1) and forced vital capacity (FVC). Regular spirometry testing provides essential information for managing and adjusting treatment plans.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 10: Diagnosis and Treatment of COPD

Diagnosis of COPD involves assessing symptoms, medical history, and performing spirometry to confirm airflow limitation. Treatment typically includes a combination of medications like bronchodilators and inhaled corticosteroids to manage symptoms and improve lung function. Additionally, lifestyle changes such as smoking cessation, pulmonary rehabilitation, and regular monitoring are crucial for managing the disease and enhancing quality of life.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 11: Pulmonary Rehabilitation

Pulmonary rehabilitation is a comprehensive program designed to improve the quality of life for individuals with chronic respiratory conditions. It includes supervised exercise training, education on disease management, and psychological support, aiming to enhance physical fitness, reduce symptoms, and help patients better manage their condition.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 12: Respiratory Failure

Respiratory failure occurs when the lungs are unable to adequately oxygenate the blood or remove carbon dioxide, leading to low blood oxygen levels or elevated carbon dioxide levels. It can result from acute or chronic conditions, requiring prompt medical intervention to stabilize breathing and address the underlying cause, often through supplemental oxygen, mechanical ventilation, or specific treatments tailored to the condition.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 13: Lung and COVID-19

Lung complications from COVID-19 can range from mild inflammation to severe respiratory distress, as the virus primarily affects the lungs, causing damage and impairing oxygen exchange. Severe cases may lead to acute respiratory distress syndrome (ARDS) and require intensive care, including mechanical ventilation. Ongoing research aims to understand long-term lung effects and improve treatment strategies for COVID-19-related lung damage.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 14: Effect of COVID-19 on Lungs

COVID-19 can cause significant damage to the lungs, leading to symptoms such as severe inflammation, impaired oxygen exchange, and acute respiratory distress syndrome (ARDS). The virus can disrupt lung tissue and exacerbate underlying conditions, resulting in long-term respiratory issues for some patients. Effective management and ongoing research are crucial for addressing the full impact of COVID-19 on lung health.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 15: Lung Transplantation

Lung transplantation is a surgical procedure where a diseased lung is replaced with a healthy donor lung to improve respiratory function and quality of life. It is typically considered for patients with end-stage lung diseases such as severe COPD or cystic fibrosis, and requires careful donor matching, rigorous post-operative care, and lifelong immunosuppressive therapy to prevent rejection.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 16: Self-Management and Prevention of COPD

Self-management and prevention of COPD involve strategies to control symptoms and slow disease progression, such as adhering to prescribed medications, avoiding triggers like smoke and pollutants, and engaging in regular exercise. Education on recognizing early symptoms, proper inhaler use, and lifestyle adjustments like quitting smoking are crucial for maintaining optimal lung health and enhancing overall well-being.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 17: Depression and Anxiety in COPD

Depression and anxiety are common among individuals with COPD, often exacerbated by the chronic nature of the disease and its impact on daily life. These mental health conditions can worsen symptoms and hinder effective management, making it essential to address them through integrated care that includes psychological support, counseling, and appropriate treatment alongside respiratory therapies.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 18: Clinical Immunology & Genetics

Clinical immunology and genetics explore the roles of the immune system and genetic factors in the development and progression of diseases. In respiratory conditions like asthma and COPD, understanding genetic predispositions and immune responses can inform personalized treatment strategies and improve disease management by targeting specific pathways involved in inflammation and immune regulation.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 19: Experimental Models

Experimental models of COPD and asthma are essential for studying disease mechanisms and testing new treatments. These models, including animal studies and cell cultures, help researchers understand the underlying pathology, evaluate drug efficacy, and develop targeted therapies, ultimately advancing knowledge and improving clinical outcomes for patients with these chronic respiratory conditions.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 20: Epidemiology

Epidemiology in respiratory diseases focuses on understanding the distribution and determinants of conditions like COPD and asthma within populations. By analyzing patterns, risk factors, and trends, epidemiologists provide valuable insights into disease prevalence, causes, and impacts, which inform public health strategies and guide preventive measures to reduce the burden of these chronic conditions.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Track 21: Clinical Trials

Clinical trials for COPD and asthma investigate new treatments, therapies, and management strategies to improve patient outcomes. These trials evaluate the safety and efficacy of medications, devices, and interventions through rigorous testing and monitoring. Results from clinical trials contribute to advancing medical knowledge and developing evidence-based approaches for more effective and personalized care in these chronic respiratory conditions.

Related Conferences: COPD Summit 2025 | Pulmonology Conferences | Lung Health Meetings | Respiratory Disease Conferences

Related Worldwide Associations and Societies:

American Thoracic Society | American Lung Association | World Health Organization | Primary Care Respiratory Society

Benifit of Participation

Benefits for Speaker

• Gain global recognition for your research profile worldwide.
• Earn professional credits to support your career advancement.
• Stay updated with the latest advancements in cutting-edge research.
• Foster lasting connections through social and networking events.
• Promote your research effectively through a one-page ad featured in abstract books and flyers, reaching a million views and significantly enhancing your research profile.
• Expand your knowledge beyond your core field of COPD by exploring new subjects and areas of study.
• Experience a unique blend of networking, learning, and enjoyable interactions, all in one comprehensive package.

Benefits for Delegate

• Enhance your professional development by deepening your understanding and knowledge.
• Your involvement contributes to the development of innovative methodologies and ideologies that can expand business and industry outcomes.
• Connect with fellow COPD summit researchers and experts, fostering opportunities to exchange fresh ideas and insights within the field.

Benefit for Sponsor

• Immerse yourself in an international environment to enhance the potential for new company opportunities.
• Showcase your company's latest technologies, new products, or services to a diverse global audience.
• Boost your business growth by generating leads through active participation.
• Building a successful company requires considerable time, effort, and determination. It's invaluable to have a network of colleagues and associates who share a common drive and objective to draw inspiration from.
• Evaluate and advance your organizational strategies by benchmarking against leading industry plans.
• Gain valuable insights and solutions to your company's questions and challenges through feedback from trusted experts during our webinars.
• Elevate your company's branding and marketing through prominent placement of your company's logo on our banners, website, and other event materials.

Benefit for Collaborators

• This is the premier platform globally for showcasing COPD to an extensive audience.
• Cultivate enduring professional relationships.
• Elevate your subscriber/member base by 40% through strategic placement of your organization's branding, marketing materials, promotional content, and logo on our banners, website, and event materials.
• Listing your company in the Global Business forum will significantly amplify its exposure through our event.
• Your representatives can engage in valuable networking opportunities to enhance their knowledge and understanding of your organization's services and offerings alongside key delegates.
• COPD advertising materials, including posters, brochures, pamphlets, and services, will be seamlessly integrated with information and distributed to hospitals, universities, societies, and researchers.

Who Should Attend?

• Medical Professionals & Healthcare Providers
• Research Scientists & Clinical Specialists
• Pharmaceutical Experts & Pulmonary Experts
• Allergy Specialists & Academic Researchers
• Public Health Experts & Medical Educators
• Disease Advocates & Policy Makers
• Respiratory Therapists & Healthcare Administrators
• Medical Students

Market Analysis

The Chronic Obstructive Pulmonary Disease (COPD) market was valued at USD 20.84 billion in 2023 and is expected to grow significantly over the next decade. Projections indicate an increase from USD 22.07 billion in 2024 to USD 33.72 billion by 2032, representing a compound annual growth rate (CAGR) of 4.82% from 2024 to 2032.

This growth is driven by the rising global prevalence of COPD and the growing adoption of more effective combination therapies. As the demand for advanced treatment options increases, the market continues to expand, reflecting both the need for better management of COPD and the advancements in therapeutic strategies.